## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):

Kirvin L. Hodge, et al.

Atty. Ref.:

18030-PCTUS

Appl. No.:

10/531,630

Group Art Unit:

1621

Filed:

April 14, 2005

Examiner:

Carr, Deborah

Customer No.: 31976

Conf. No.:

8412

For:

COMPOUNDS FOR THE TREATMENT OF METABOLIC

DISORDERS

September 26, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO/SB/08a. A copy of the pending claims in U.S. Application Nos. 11/481508, 11/772501, 11/772504, 11/772511, 11/772515, 11/772520, 11/772556, 11/772560, 11/844431, 11/844432, 11/841489, 10/566302, and 11/909120 are enclosed. The other documents listed are U.S. patents and U.S. patent application publications.

On August 10, 2007 claims 1-5, 7-11, 67, 70-73, 77, 83, 85, 87, 89, 92 and 94 of Application No. 11/535,779 (Pub. No. U.S. 2007/0105958) were provisionally rejected for alleged obviousness-type double patenting over claims 6-13, 24 and 34-41 of the subject application in view of claim 10 of U.S. Patent No. 7,101,910.

Inventor(s): Hodge, et al. Application No.: 10/531,630

Page 2

It is believed that no fee, other than the fee for consideration of an information disclosure statement, is required in connection with the filing of this Statement. If any additional fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,

Lewis J. Kreisler Reg. No. 38522

Attorney for Applicant(s)

930 Clopper Road

Gaithersburg, MD 20878

Phone: (240) 631-2500 x3276 Facsimile: (240) 683-3794